FDA signals a quick approval for Shire's ADHD drug

Fresh from inking a pact for Juvista, Shire announced that the FDA had issued an approvable letter for its ADHD drug Intuniv. The agency has requested additional information on the therapy but Shire noted that the request was not unexpected and the company is on track to launch the drug next year. Intuniv is a non-stimulant therapy, which should give it an advantage over the stimulants on the market for ADHD.

- see the release
- read the AP report on the FDA action

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.